Summary Limonene, a monocyclic monoterpene, occurs naturally in orange peel oil. It has been shown to exhibit both chemopreventive and chemotherapeutic activity without toxicity in rodent models. In this study we examined the effect of limonene both at maximally optimal and suboptimal doses and in combination with suboptimal doses of 4-hydroxyandrostrenedione on nitrosmethylurea-induced rat mammary tumours. A 10% limonene dose mixed in the diet caused tumour regression in all animals. A 5% limonene dose was only able to cause regression in 50% of the rats (P <0.05). A suboptimal dose of 4-hydroxyandrostrenedione (12.5mgkg 1) resulted in tumour re ression in 75% of rats. A combination of 5% limonene with 4-hydroxyandrostrenedione (12.5mgkg-) resulted in a greater tumour regression (83.3%) than either agent given individually (P <0.001 and 0.006 for limonene/4-hydroxyandrostrenedione vs limonene alone and 4-hydroxyandrostrenedione alone respectively).
The monocyclic monoterpene limonene is a natural product constituting up to 95% of orange peel oil and a considerable proportion of many other essential oils. Limonene has significant chemopreventive and chemotherapeutic activity without toxicity in rodents (Elegbede et al., 1984 (Elegbede et al., , 1986 Elson et al., 1988; Maltzman et al., 1989; Wattenberg et al., 1989 Wattenberg et al., , 1991 . Most studies have been directed at the use of limonene in the prevention of carcinogen-induced cancer (Wattenberg et al., 1983; Elegbede et al., 1984) . It has been shown that limonene inhibits rat mammary carcinomas induced by both the indirectly acting carcinogen DMBA (Elegbede et al., 1984) and the directly acting carcinogen NMU (Maltzman et al., 1989) . The inhibitory effect of limonene was observed at both the initiation and promotion/progression stages for DMBA-induced cancers (Elson et al., 1988) , but only at the promotion/progression stage for NMU-induced mammary cancer (Maltzman et al., 1989) .
The suppressive activity of limonene during the promotion phase of rat mammary carcinogenesis has been demonstrated in both chemical carcinogen (Maltzman et al., 1989) and ras-induced (Moore et al., 1991) model systems. Rats fed a diet containing 5% limonene during the promotion phase only of the NMU model exhibited longer latency and approximately 5-fold fewer tumours than controls (Maltzman et al., 1989) .
It has been shown that limonene can selectively inhibit protein isoprenylation (Crowell et al., 1991) , a posttranslational modification in which an isoprene group is covalently attached to the carboxy terminus. Most of the isoprenylated proteins affected by limonene have a molecular weight of 20,000-26,000 (Crowell et al., 1991) and are small G-proteins such as the members of the p21 -ras family (Maltese et al., 1990) .
The effectiveness of limonene alone on NMU-induced rats has already been shown by previous workers (Haag et al., 1992) . In this study the possibility of using limonene in combination with 4-hydroxyandrostenedione (4-HAD), a potent aromatase inhibitor, was investigated to explore whether the inhibitory activity of suboptimal doses of 4-HAD and limonene when given together could result in greater inhibition of NMU-induced tumour growth than either of these agents alone. Such an approach could open new avenues for using limonene in combination therapy.
Materials and methods
In vivo studies Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumours induced with NMU were supplied by Olac (Oxon, UK). These were used in the manner described previously (Wilkinson et al., 1986 4-Hydroxyandrostrendione alone A suboptimal dose of 12.5 mg kg-' 4-HAD (Ciba Geigy) was resuspended in saline and formed a white suspension, which was administered daily at a dose of 12.5 mg kg-' (2.5 mg 0.1 ml-' per rat) subcutaneously for 4 weeks. A dose of 50 mg kg-' 4-HAD has previously been shown to be maximally effective (Wilkinson et al., 1986 Histological studies At the end of the 4 week period of drug treatment animals were sacrificed and tumours were resected and immediately frozen in liquid nitrogen. Frozen sections (8 ftm) were stained using standard haematoxylin and eosin, and examined for morphological changes.
Results

Limonene treatment
The effect of 10% limonene in the diet on the growth of NMU-induced tumours is shown in Figure 1 . After 4 weeks' treatment, limonene produced tumour regression in all rats. Eighty-six per cent of the animals (13/15) exhibited greater than 50% tumour regression (Table I ). Any new tumours that occurred after commencement of treatment also subsequently regressed in the limonene group. In the control group two (13.3%) rats showed tumour regression. Thus, limonene treatment produced a significantly beneficial response compared with control (Mann-Whitney U = 1, P <0.05). We observed no weight loss at this dose of limonene.
Limonene in combination with 4-hydroxyandrostenedione The combination of suboptimal doses of 4-HAD with a suboptimal dose of limonene (5%) was compared and the results are shown in Figure 2 . A 5% limonene dose only produced overall tumour regression of 50% (6/12) of rats, progression. aMann-Whitney U = 1, P < 0.05. but only 25% of animals showed > 50% tumour regression. 4-HAD administered alone caused regression in 75% (9/12) of rats. Moreover, 58% (7/12) of rats showed > 50% tumour regression. However, in combination, limonene plus 4-HAD caused regression in 83.3% (10/12) of rats, and this level of response was significantly greater than that achieved with the individual agents alone (P-values as given in Table II (Figure 3 ). Epithelia were commonly multilaminate. In some tumours, large acinar cavities or cysts were present and containing variable amounts of cell debris. Four of the tumours were welldifferentiated carcinomas; their cellularity was more intense and papillary tufts prominent.
Limonene-treated group Two tumours out of 15 examined were quite benign. They contained some large debris-filled cavities, showed no evidence of proliferative activity and consisted of acinar tissue interspersed with connective tissue characteristic of adenocarcinoma, but for the most part the tissue was hypocellular, fragmentary and regressive ( Figure  4 ). Some residual evidence of malignancy in the form of papillary tufts with pleomorphic cells and hypocellularity was seen, but mitotic activity was very low. These tumours exhibited fragmentary epithelia and were generally regressive.
Those rats treated with the combination of limonene and 4-HAD also showed similar characteristics to the limonenetreated groups.
Discussion
Data presented in this study support previous findings that a 10% limonene dose in the diet is sufficient to cause tumour regression (Haag et al., 1992) ; limonene showed regression in 100% of rats, and 86.6% of rats showed >50% regression from the initial tumour volume. The histological studies showed that treatment with limonene caused regression of tumour mass, as most of the tissue showed regressive fragmentary epithelia.
The most significant finding was that suboptimal doses of an aromatase inhibitor, 4-HAD, could be used in combination with a suboptimal dose of limonene to produce regression in rats similar to that obtained with maximally effective doses of either limonene or 4-HAD separately. This suggests that the full potential of limonene in the treatment of breast cancer can be realised in a combination therapy minimising risk of toxicity, which might occur if higher doses were used in chronic treatment.
The mode of action of 4-HAD has been well studied (Coombes et al., 1984) 
